fulvestrant has been researched along with Lung Neoplasms in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (21.05) | 29.6817 |
| 2010's | 25 (65.79) | 24.3611 |
| 2020's | 5 (13.16) | 2.80 |
| Authors | Studies |
|---|---|
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K | 1 |
| Almotlak, AA; Farooqui, M; Siegfried, JM | 1 |
| Ai, B; Cao, X; Fan, S; Li, D; Li, L; Liao, Y; Qiu, W | 1 |
| Gaofeng, P; Hexiao, T; Jinping, Z; Lanuti, M; Lecai, X; Li, S; Li, Z; Ming, X; Minglin, Z; Weidong, H; Xiao, Z; Xuefeng, Z; Yanhong, W; Yi, C; Yuquan, B; Zetian, Y; Zheng, T | 1 |
| Dacic, S; Farooqui, M; Rothenberger, NJ; Siegfried, JM; Stabile, LP | 1 |
| Fan, S; Fu, X; Liao, Y; Liu, C; Wang, J; Xiong, J; Zhou, S; Zou, M | 1 |
| Liu, C; Wang, H; Wang, R; Xia, D; Xu, J | 1 |
| O'Leary, KA; Schuler, LA; Shea, MP; Vezina, CM; Wegner, KA | 1 |
| Adams, B; Brennan, M; Dacic, S; Davenport, S; Dubinett, SM; Elashoff, D; Elashoff, RM; Garon, EB; Grogan, T; Hu, EH; Marquez-Garban, DC; Parikh, RJ; Park, DJ; Patel, R; Pietras, RJ; Press, MF; Reckamp, KL; Sadeghi, S; Siegfried, JM; Slamon, DJ; Stabile, LP; Valdes, Y; Wang, HJ; Young, PA | 1 |
| Gibson, K; Iyer, S; Milligan, G; Mitra, D; Taylor-Stokes, G; Waller, J | 1 |
| Duraki, D; Helferich, WG; Huang, R; Kim, JE; Mao, C; Nelson, ER; Park, BH; Shapiro, DJ; Wang, L; Yu, L | 1 |
| He, M; Hu, XC; Ji, L; Jiang, YZ; Li, JJ; Shao, ZM; Wang, ZH; Zuo, WJ | 1 |
| Henske, EP; Li, C; Mancini, JD; Morrison, TA; Parkhitko, A; Silverman, EK; Sun, Y; Yu, JJ; Zhang, E; Zhou, X | 1 |
| Chen, Q; Li, Q; Liu, J; Qian, X; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, R; Xu, T; Zheng, J | 1 |
| Siegfried, JM | 1 |
| Chen, G; Fu, S; Liao, Y; Liu, Z; Tang, H; Xu, L; Yu, L; Zhang, C; Zhou, S | 1 |
| Fan, S; Jiang, Z; Liao, Y; Liu, C; Tang, H; Wang, J; Xiong, J; Zhou, B; Zhou, S; Zou, M | 1 |
| An, T; Bai, H; Ding, X; Duan, J; Li, Z; Liu, Z; Shen, Z; Sun, Y; Wang, J; Wang, S; Wang, Y; Wang, Z; Wu, M; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Brosseau, S; Naltet, C; Oulkhouir, Y; Zalcman, G | 1 |
| David, JM; Ferrer, M; Griner, LM; Hamilton, DH; Hu, X; Keller, JM; Marugan, J; Palena, C; Southall, N | 1 |
| Endo, T; Hasegawa, K; Higashi, Y; Kamiya, A; Kaneko, J; Kondo, I; Maejima, S; Takatsuno, Y | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Bines, J; Mauriac, L; Romieu, G | 1 |
| Dougherty, SM; Ivanova, MM; Klinge, CM; Mazhawidza, W | 1 |
| Aranda, E; Berciano Guerrero, M; de la Haba Rodríguez, JR; Porras Quintela, I; Pulido Cortijo, G | 1 |
| Abe, K; Akahira, J; Evans, DB; Hata, S; Iida, S; Kondo, T; Miki, Y; Mori, K; Niikawa, H; Sasano, H; Suzuki, S; Suzuki, T; Yamada-Okabe, H | 1 |
| Cao, JH; Davis, FB; Davis, PJ; Hercbergs, A; Lin, HY; London, D; Luidens, M; Meng, R; Mousa, SA; Tang, HY; Westfall, J | 1 |
| Gubish, CT; Henry, C; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Abe, K; Miki, Y; Niikawa, H; Sasano, H; Verma, MK | 1 |
| Gao, W; Guo, R; Shen, H; Shu, Y; Sun, J; Xu, R | 1 |
| Cunningham, DE; Dacic, S; Keohavong, P; Land, SR; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Dering, J; Desai, AJ; Dubinett, SM; Finn, RS; Garon, EB; Hosmer, W; Kamranpour, N; Márquez-Garbán, DC; Pietras, RJ; Pitts, S; Slamon, DJ; von Euw, EM | 1 |
| Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J | 1 |
| Grandis, JR; Gubish, CT; Lyker, JS; Siegfried, JM; Stabile, LP; Zhang, W | 1 |
| Hershberger, PA; Kanterewicz, B; Land, S; Nichols, M; Siegfried, JM; Vasquez, AC | 1 |
| Hoffman, MA; Khan, A | 1 |
| Cathiard, AM; Chambon, M; Garcia, M; Maynadier, M; Nirdé, P; Platet, N; Ramirez, JM | 1 |
3 review(s) available for fulvestrant and Lung Neoplasms
| Article | Year |
|---|---|
High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tomography, X-Ray Computed | 2018 |
Smoking out reproductive hormone actions in lung cancer.
Topics: Aromatase; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Lung; Lung Neoplasms; Male; Smoking; Testosterone | 2014 |
[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cetuximab; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Fulvestrant; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Translocation, Genetic | 2015 |
3 trial(s) available for fulvestrant and Lung Neoplasms
| Article | Year |
|---|---|
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Viscera | 2009 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2003 |
32 other study(ies) available for fulvestrant and Lung Neoplasms
| Article | Year |
|---|---|
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local | 2022 |
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites | 2023 |
Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Fulvestrant; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Movement; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Sulfonamides; Toll-Like Receptor 4 | 2020 |
Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERβ2/5 pathway.
Topics: Adenocarcinoma of Lung; Animals; Chromosomal Proteins, Non-Histone; Computational Biology; Databases, Factual; Disease Progression; Estrogen Receptor Antagonists; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Microfilament Proteins; Signal Transduction | 2021 |
Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Estradiol; Estrogens; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Ligands; Lung Neoplasms; Mice; Neoplastic Stem Cells; Piperazines; Protein Binding; Pyrazoles; Receptors, Estrogen; Receptors, Fibroblast Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
G-Protein-Coupled Estrogen Receptor Antagonist G15 Decreases Estrogen-Induced Development of Non-Small Cell Lung Cancer.
Topics: A549 Cells; Adenocarcinoma; Animals; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Estrogen Receptor Antagonists; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Humans; Lung Neoplasms; Mice; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Urethane | 2019 |
High collagen density augments mTOR-dependent cancer stem cells in ERα+ mammary carcinomas, and increases mTOR-independent lung metastases.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Microenvironment | 2018 |
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Piperazines; Practice Patterns, Physicians'; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Neoplasm Invasiveness; Proto-Oncogene Proteins c-myc; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Decision-Making; Diagnosis, Differential; Disease Management; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Treatment Outcome | 2019 |
Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.
Topics: Airway Remodeling; Animals; Antineoplastic Agents; Collagen Type IV; Drug Evaluation, Preclinical; Estradiol; Extracellular Matrix; Female; Fulvestrant; Lung; Lung Neoplasms; Lymphangioleiomyomatosis; Male; Matrix Metalloproteinase 2; Mice; Mice, SCID; Rats; Receptors, Estradiol; Survival Analysis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transfection; Up-Regulation | 2014 |
Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents, Hormonal; Carcinogenesis; Disease Models, Animal; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Middle Aged; Signal Transduction; Tissue Array Analysis; Urethane | 2014 |
G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
Topics: Adenocarcinoma; Aged; Animals; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Movement; Cell Proliferation; Cyclopentanes; Disease Progression; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Tissue Array Analysis; Tumor Cells, Cultured; Urethane; Xenograft Model Antitumor Assays | 2015 |
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; China; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Male; MCF-7 Cells; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2015 |
Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Killer Cells, Natural; Lung Neoplasms; Signal Transduction; T-Lymphocytes | 2016 |
[Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Lung Neoplasms; Nitriles; Treatment Outcome; Triazoles | 2016 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Nucleus; Cyclin D1; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fluorescence; Fulvestrant; Genome, Human; Humans; Lung Neoplasms; Male; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Mutant Proteins; Phosphoserine; Protein Transport; Sex Characteristics; Signal Transduction; Subcellular Fractions; Tamoxifen | 2010 |
Fulvestrant in advanced male breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Estradiol; Fulvestrant; Humans; Lung Neoplasms; Male; Mastectomy, Radical; Radiotherapy | 2009 |
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Topics: Aged; Androgens; Aromatase; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Coculture Techniques; Estradiol; Estrogens; Female; Fulvestrant; Humans; Immunohistochemistry; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Oncostatin M; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Necrosis Factor-alpha | 2010 |
Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells.
Topics: Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Fulvestrant; Humans; Integrin alphaVbeta3; Lung Neoplasms; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein Transport; Signal Transduction; Thyroid Hormones; Thyroxine | 2011 |
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Cytoplasmic estrogen receptor β as a potential marker in human non-small cell lung carcinoma.
Topics: Aromatase; Biomarkers, Tumor; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immunohistochemistry; Lung Neoplasms; Nitriles | 2012 |
Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Receptors, Estrogen; Signal Transduction; Up-Regulation | 2012 |
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Carcinogens; Cell Proliferation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nicotiana; Nitriles; Nitrosamines; Receptors, Estrogen; Triazoles | 2012 |
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 2013 |
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2005 |
Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lung Neoplasms; Nuclear Receptor Coactivator 2; Receptors, Estrogen; Transcription Factors | 2005 |
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Lung Neoplasms; Nitriles; Progestins; Triazoles | 2006 |
Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Receptors, Estrogen; Transcription, Genetic; Tumor Cells, Cultured; Zinc Fingers | 2008 |